Tirzepatide denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Tirzepatide as Duplicate Therapy — and Why You Can Appeal

A duplicate-therapy denial from UnitedHealthcare (UHC) means the plan believes you are already receiving a medication it considers therapeutically equivalent to tirzepatide. This most commonly occurs when a patient is on another GLP-1 receptor agonist or diabetes/obesity medication. However, tirzepatide has a distinct mechanism of action, and a duplicate-therapy label may not be clinically accurate.

## Why This Denial Is Appealable

Duplicate-therapy determinations are a clinical judgment call, not just an administrative one. Tirzepatide's dual mechanism differs from single-receptor agents, and your prescriber may have a documented clinical rationale for why the existing therapy is insufficient and why the mechanisms are not interchangeable for your situation. UHC's clinical review must engage with that rationale — it cannot simply equate drug classes without addressing clinical distinction.

## Federal Appeal Framework

• Internal appeal: ERISA §503 (employer plans) or state law (other plans) guarantees a full-and-fair internal review. File by the deadline on your denial notice — typically 180 days.
• External review: Under ACA §2719, you may request independent external review after exhausting internal remedies. The external-review window is generally within approximately four months of the final internal denial. External reviewers are independent clinicians not employed by UHC.
• Expedited review: Available when delay would seriously jeopardize your health; typically decided within 72 hours.

## Concrete Appeal Steps

1. Obtain the denial letter and identify which medication UHC claims duplicates tirzepatide. 2. Ask your prescriber to prepare a letter distinguishing the mechanisms and explaining the clinical inadequacy of the current therapy for your specific case. 3. Document current therapy's outcomes: labs, weight trajectory, glycemic control records, adverse effects — whatever is clinically relevant per your chart. 4. Submit your internal appeal with supporting documentation. 5. If denied internally, file for external review and request an independent clinical reviewer.

## Documentation to Gather

• Current therapy records: Documentation of what medications you are on, start dates, dosing, and clinical response (or lack thereof).
• Prescriber medical-necessity letter: A letter specifically addressing the claimed duplication, explaining the clinical distinction and why tirzepatide is not duplicative for this patient.
• Lab and monitoring records: Objective data (A1C trends, weight records, relevant metabolic markers) showing the current regimen's limitations.
• Diagnosis documentation: Chart notes confirming the underlying diagnoses being treated.

## Criteria-Mapping Structure

For each criterion UHC cited in the duplicate-therapy determination, create a response column citing the specific chart evidence. In particular, address the claimed equivalent drug directly: quote your prescriber's explanation of why the mechanisms differ clinically for your case. Attach relevant lab trends as exhibits to make the clinical inadequacy of existing therapy concrete and objective.